Cns Pharmaceuticals Inc

NASDAQ:CNSP   3:59:17 PM EDT
0.28
+0.02 (+6.39%)
Products

CNS Receives U.S. FDA Approval For Protocol Amendment To Trial Evaluating Berubicin

Published: 06/23/2022 13:00 GMT
Cns Pharmaceuticals Inc (CNSP) - Cns Pharmaceuticals Receives Approval From U.S. FDA for Protocol Amendment to Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of Gbm.